Korea Biomedical Reviewㅣ 2024-11-15 Medical AI company Mediwhale will release three research abstracts on its AI-powered cardiovascular disease (CVD) prediction software, Reti-CVD, at the American Heart Association’s (AHA) Scientific Sessions 2024, which will be held...
Korea Biomedical Review | 2024-06-27 Mediwhale, a medical AI diagnostic solution provider, said Thursday that it has been selected as a “JLABS” company, benefitting from a global accelerator platform operated by Johnson & Johnson Innovation, a multinational...
Mediwhale Inc. (hereinafter referred to as the “Company”) values your privacy and complies with the Personal Data Protection Act. Through this Privacy Policy, we will inform you of the purpose and manner in which the personal information you provide is...
Privacy policy Mediwhale Inc. (“Mediwhale,” “we, “us,” or “our”) establishes and presents the following privacy policy describing how and why we might collect, store, use, share and/or protect your personal information who use Mediwhale’s website and resolve any...
This website (“Web Site”) is offered to you by Mediwhale, Inc. (“Mediwhale”). The following Terms of Use govern your access and use of this Web Site and its service. Also, specific terms and conditions may apply to specific content, data, materials, or information...
American Heart Association consortium advances development of evidence-based health tech solutions [Seoul, Korea, Sep 30, 2022] – Mediwhale, a retina-based AI company, has joined the American Heart Association Center for Health Technology & Innovation’s...
